BR112022006304A2 - N-(1H-IMIDAZOLE-2-IL)BENZAMIDE COMPOUND, OR A SALT, A PRODrug, A SOLVATE OR A PHARMACEUTICALLY ACCEPTABLE STEREOISOMER THEREOF, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME AS AN ACTIVE INGREDIENT AND USES THEREOF TO PREVENT OR TREAT A IRAK4 MEDIATED DISEASE OR TO INHIBIT IRAK4 - Google Patents
N-(1H-IMIDAZOLE-2-IL)BENZAMIDE COMPOUND, OR A SALT, A PRODrug, A SOLVATE OR A PHARMACEUTICALLY ACCEPTABLE STEREOISOMER THEREOF, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME AS AN ACTIVE INGREDIENT AND USES THEREOF TO PREVENT OR TREAT A IRAK4 MEDIATED DISEASE OR TO INHIBIT IRAK4Info
- Publication number
- BR112022006304A2 BR112022006304A2 BR112022006304A BR112022006304A BR112022006304A2 BR 112022006304 A2 BR112022006304 A2 BR 112022006304A2 BR 112022006304 A BR112022006304 A BR 112022006304A BR 112022006304 A BR112022006304 A BR 112022006304A BR 112022006304 A2 BR112022006304 A2 BR 112022006304A2
- Authority
- BR
- Brazil
- Prior art keywords
- irak4
- prodrug
- solvate
- pharmaceutically acceptable
- salt
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPOSTO N-(1H-IMIDAZOL-2-IL)BENZAMIDA, OU UM SAL, UM PRÓ-FÁRMACO, UM SOLVATO OU UM ESTEREOISÔMERO FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÕES FARMACÊUTICA COMPREENDENDO OS MESMOS COMO INGREDIENTE ATIVO E USOS DOS MESMOS PARA PREVENIR OU TRATAR UMA DOENÇA MEDIADA POR IRAK4 OU PARA INIBIR IRAK4. Composto N-(1H-imidazol-2-il)benzamida de fórmula (I), ou um sal, um prófármaco, um solvato ou um estereoisômero farmaceuticamente aceitável do mesmo que é um composto inovador que exibe excelente atividade inibitória contra IRAK-4, pode ser usado sem efeitos colaterais para a prevenção e o tratamento eficientes de doenças mediadas por receptores de IRAK-4, particularmente doenças autoimunes ou linfomas.N-(1H-IMIDAZOLE-2-IL)BENZAMIDE COMPOUND, OR A SALT, A PRODrug, A SOLVATE OR A PHARMACEUTICALLY ACCEPTABLE STEREOISOMER THEREOF, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME AS AN ACTIVE INGREDIENT AND USES THEREOF TO PREVENT OR TREAT A IRAK4 MEDIATED DISEASE OR TO INHIBIT IRAK4. N-(1H-imidazol-2-yl)benzamide compound of formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, or stereoisomer thereof which is an innovative compound that exhibits excellent inhibitory activity against IRAK-4, can be used without side effects for the efficient prevention and treatment of diseases mediated by IRAK-4 receptors, particularly autoimmune diseases or lymphomas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962909498P | 2019-10-02 | 2019-10-02 | |
| KR2021066559 | 2021-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022006304A2 true BR112022006304A2 (en) | 2022-06-28 |
Family
ID=83355823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022006304A BR112022006304A2 (en) | 2019-10-02 | 2020-09-29 | N-(1H-IMIDAZOLE-2-IL)BENZAMIDE COMPOUND, OR A SALT, A PRODrug, A SOLVATE OR A PHARMACEUTICALLY ACCEPTABLE STEREOISOMER THEREOF, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME AS AN ACTIVE INGREDIENT AND USES THEREOF TO PREVENT OR TREAT A IRAK4 MEDIATED DISEASE OR TO INHIBIT IRAK4 |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BR112022006304A2 (en) |
-
2020
- 2020-09-29 BR BR112022006304A patent/BR112022006304A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| CO2019015090A2 (en) | Treatment methods for cystic fibrosis | |
| CO2017011795A2 (en) | Topical pharmaceutical compositions | |
| EA201891703A1 (en) | COMPOUNDS OF BENZOPIRAZOL AND THEIR ANALOGUES | |
| BR112017017009A2 (en) | uses of a formaldehyde scavenger and pharmaceutical composition, methods for preventing, delaying, slowing or slowing transformation of a compound and for treating cancer, and pharmaceutical composition. | |
| PE20191650A1 (en) | INDOLINE DERIVATIVES SUBSTITUTED AS INHIBITORS OF DENGUE VIRAL REPLICATION | |
| BR112021007788A8 (en) | Jak 2-azabicyclohexane inhibitor compound | |
| CO2023002852A2 (en) | Functionalized peptides as antiviral agents | |
| AR085662A1 (en) | METHODS AND COMPOSITIONS TO TREAT HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA | |
| BR112021026397A2 (en) | ep2 antagonist | |
| BR112022016360A2 (en) | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF FELINE HEART DISEASES | |
| MA43052B1 (en) | Human Plasma Kallikrein Inhibitors | |
| MX2022000945A (en) | Composition for increasing expression of pgc-1î±. | |
| AR117655A1 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION, INCLUDING A DERIVATIVE OF AMINOPYRIMIDINE OR ITS SALT | |
| CO2021000229A2 (en) | Pyrazole and imidazole compounds for the inhibition of yl-17 and rorgamma | |
| EP4234021A3 (en) | Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy | |
| BR112019018028A2 (en) | COMPOUND, COMBINATION, E. USE OF A PHARMACEUTICALLY ACCEPTABLE COMPOUND OR SALT OF THE SAME | |
| BR112022006304A2 (en) | N-(1H-IMIDAZOLE-2-IL)BENZAMIDE COMPOUND, OR A SALT, A PRODrug, A SOLVATE OR A PHARMACEUTICALLY ACCEPTABLE STEREOISOMER THEREOF, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME AS AN ACTIVE INGREDIENT AND USES THEREOF TO PREVENT OR TREAT A IRAK4 MEDIATED DISEASE OR TO INHIBIT IRAK4 | |
| BR112021019779A2 (en) | Novel compound and composition for preventing or treating respiratory diseases comprising the same as an active ingredient | |
| MX2022003830A (en) | N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient. | |
| CO2020001881A2 (en) | Synergistic pharmaceutical combination of the active enantiomer s-ketorolac tromethamine and tramadol hydrochloride | |
| BR112017016278A2 (en) | Prevention and/or the medical treatment agent of immunopathy | |
| EP3789040A4 (en) | Preventive and/or therapeutic agent for autoimmune disease comprising compound having btk inhibitory activity as active ingredient | |
| CO2022008209A2 (en) | Compound that functions as a pdgf receptor kinase inhibitor and composition | |
| BR112023019657A2 (en) | ABHD6 ANTAGONIST |